256 related articles for article (PubMed ID: 8700512)
21. Activation of the endogenous p53 growth inhibitory pathway in HeLa cervical carcinoma cells by expression of the bovine papillomavirus E2 gene.
Hwang ES; Naeger LK; DiMaio D
Oncogene; 1996 Feb; 12(4):795-803. PubMed ID: 8632901
[TBL] [Abstract][Full Text] [Related]
22. CSF-1 activates MAPK-dependent and p53-independent pathways to induce growth arrest of hormone-dependent human breast cancer cells.
Lee AW; Nambirajan S; Moffat JG
Oncogene; 1999 Dec; 18(52):7477-94. PubMed ID: 10602507
[TBL] [Abstract][Full Text] [Related]
23. Transforming growth factor beta 1 increases the stability of p21/WAF1/CIP1 protein and inhibits CDK2 kinase activity in human colon carcinoma FET cells.
Gong J; Ammanamanchi S; Ko TC; Brattain MG
Cancer Res; 2003 Jun; 63(12):3340-6. PubMed ID: 12810668
[TBL] [Abstract][Full Text] [Related]
24. Heregulin-dependent autocrine loop regulates growth of K-ras but not erbB-2 transformed rat thyroid epithelial cells.
Mincione G; Piccirelli A; Lazzereschi D; Salomon DS; Colletta G
J Cell Physiol; 1998 Aug; 176(2):383-91. PubMed ID: 9648926
[TBL] [Abstract][Full Text] [Related]
25. Heregulin-beta is especially potent in activating phosphatidylinositol 3-kinase in nontransformed human mammary epithelial cells.
Ram TG; Hosick HL; Ethier SP
J Cell Physiol; 2000 Jun; 183(3):301-13. PubMed ID: 10797304
[TBL] [Abstract][Full Text] [Related]
26. Regulation of cyclooxygenase-2 pathway by HER2 receptor.
Vadlamudi R; Mandal M; Adam L; Steinbach G; Mendelsohn J; Kumar R
Oncogene; 1999 Jan; 18(2):305-14. PubMed ID: 9927187
[TBL] [Abstract][Full Text] [Related]
27. Increased cdc2 and cdk2 kinase activity by retinoid X receptor gamma-mediated transcriptional down-regulation of the cyclin-dependent kinase inhibitor p21Cip1/WAF1 correlates with terminal differentiation of squamous cell carcinoma lines.
Crowe DL; Shuler CF
Cell Growth Differ; 1998 Aug; 9(8):619-27. PubMed ID: 9716179
[TBL] [Abstract][Full Text] [Related]
28. Taxol-induced apoptosis depends on MAP kinase pathways (ERK and p38) and is independent of p53.
Bacus SS; Gudkov AV; Lowe M; Lyass L; Yung Y; Komarov AP; Keyomarsi K; Yarden Y; Seger R
Oncogene; 2001 Jan; 20(2):147-55. PubMed ID: 11313944
[TBL] [Abstract][Full Text] [Related]
29. Blocking HER-2/HER-3 function with a dominant negative form of HER-3 in cells stimulated by heregulin and in breast cancer cells with HER-2 gene amplification.
Ram TG; Schelling ME; Hosick HL
Cell Growth Differ; 2000 Mar; 11(3):173-83. PubMed ID: 10768865
[TBL] [Abstract][Full Text] [Related]
30. Different mechanisms for inhibition of cell proliferation via cell cycle proteins in PC12 cells by nerve growth factor and staurosporine.
Gollapudi L; Neet KE
J Neurosci Res; 1997 Aug; 49(4):461-74. PubMed ID: 9285522
[TBL] [Abstract][Full Text] [Related]
31. Neu differentiation factor induces ErbB2 down-regulation and apoptosis of ErbB2-overexpressing breast tumor cells.
Daly JM; Jannot CB; Beerli RR; Graus-Porta D; Maurer FG; Hynes NE
Cancer Res; 1997 Sep; 57(17):3804-11. PubMed ID: 9288791
[TBL] [Abstract][Full Text] [Related]
32. Heregulin-triggered Her-2/neu signaling enhances nuclear accumulation of p21WAF1/CIP1 and protects breast cancer cells from cisplatin-induced genotoxic damage.
Menendez JA; Mehmi I; Lupu R
Int J Oncol; 2005 Mar; 26(3):649-59. PubMed ID: 15703820
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of the melanoma cell cycle and regulation at the G1/S transition by 12-O-tetradecanoylphorbol-13-acetate (TPA) by modulation of CDK2 activity.
Coppock DL; Buffolino P; Kopman C; Nathanson L
Exp Cell Res; 1995 Nov; 221(1):92-102. PubMed ID: 7589260
[TBL] [Abstract][Full Text] [Related]
34. The outcome of heregulin-induced activation of ovarian cancer cells depends on the relative levels of HER-2 and HER-3 expression.
Xu F; Yu Y; Le XF; Boyer C; Mills GB; Bast RC
Clin Cancer Res; 1999 Nov; 5(11):3653-60. PubMed ID: 10589783
[TBL] [Abstract][Full Text] [Related]
35. Transforming growth factor-beta 1 stimulates or inhibits cell growth via down- or up-regulation of p21/Waf1.
Miyazaki M; Ohashi R; Tsuji T; Mihara K; Gohda E; Namba M
Biochem Biophys Res Commun; 1998 May; 246(3):873-80. PubMed ID: 9618305
[TBL] [Abstract][Full Text] [Related]
36. Cytoplasmic displacement of cyclin E-cdk2 inhibitors p21Cip1 and p27Kip1 in anchorage-independent cells.
Orend G; Hunter T; Ruoslahti E
Oncogene; 1998 May; 16(20):2575-83. PubMed ID: 9632134
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of the MAP kinase cascade blocks heregulin-induced cell cycle progression in T-47D human breast cancer cells.
Fiddes RJ; Janes PW; Sivertsen SP; Sutherland RL; Musgrove EA; Daly RJ
Oncogene; 1998 May; 16(21):2803-13. PubMed ID: 9652748
[TBL] [Abstract][Full Text] [Related]
38. Expression of bcl-2, c-erbB-2, p53, and p21 (waf1-cip1) protein in thyroid carcinomas.
Soda G; Antonaci A; Bosco D; Nardoni S; Melis M
J Exp Clin Cancer Res; 1999 Sep; 18(3):363-7. PubMed ID: 10606183
[TBL] [Abstract][Full Text] [Related]
39. Caveolin-1 inhibits cell detachment-induced p53 activation and anoikis by upregulation of insulin-like growth factor-I receptors and signaling.
Ravid D; Maor S; Werner H; Liscovitch M
Oncogene; 2005 Feb; 24(8):1338-47. PubMed ID: 15592498
[TBL] [Abstract][Full Text] [Related]
40. ErbB-3 mediates differential mitogenic effects of NDF/heregulin isoforms on mouse keratinocytes.
Marikovsky M; Lavi S; Pinkas-Kramarski R; Karunagaran D; Liu N; Wen D; Yarden Y
Oncogene; 1995 Apr; 10(7):1403-11. PubMed ID: 7731691
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]